Log in with your email address username.

×

Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Correspondence] C1 esterase inhibitor concentrates and attenuated androgens

Marc A Riedl and colleagues (July 25, 2017, p 1595)1 conducted a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial in 32 patients to test the prophylactic efficacy of recombinant human C1 esterase inhibitor for hereditary angio-oedema. Once or twice weekly administration of recombinant human C1 esterase inhibitor (50 IU/kg) reached the primary endpoint (reduced number of attacks) in an intention-to-treat analysis.

email